Cell proliferation and viability act as a predominant indicator for evaluating therapeutic consequences and pharmacological safety during drug development. Antibodies, particularly, can elicit proliferation inhibition or cell death in multiple mechanisms of action, including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), antibody-dependent cellular phagocytosis (ADCP), apoptosis, and other programmed cell death (PCD). Learn more: https://www.creative-biolabs.com/drug-discovery/therapeutics/cell-proliferation- |  |
By continuing to use the site, you agree to our use of cookies and to abide by our Terms and Conditions.